Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases

Repurposing has the objective of targeting existing drugs and failed, abandoned, or yet-to-be-pursued clinical candidates to new disease areas. The open-source model permits for the sharing of data, resources, compounds, clinical molecules, small libraries, and screening platforms to cost-effectively advance old drugs and/or candidates into clinical re-development. Clearly, at the core of drug-repurposing activities is collaboration, in many cases progressing beyond the open sharing of resources, technology, and intellectual property, to the sharing of facilities and joint program development to foster drug-repurposing human-capacity development. A variety of initiatives under way for drug repurposing, including those targeting rare and neglected diseases, are discussed in this review and provide insight into the stakeholders engaged in drug-repurposing discovery, the models of collaboration used, the intellectual property-management policies crafted, and human capacity developed. In the case of neglected tropical diseases, it is suggested that the development of human capital be a central aspect of drug-repurposing programs. Open-source models can support human-capital development through collaborative data generation, open compound access, open and collaborative screening, preclinical and possibly clinical studies. Given the urgency of drug development for neglected tropical diseases, the review suggests elements from current repurposing programs be extended to the neglected tropical diseases arena.

[1]  Jutta Haider,et al.  Understanding Knowledge as a Commons: From Theory to Practice , 2008, J. Documentation.

[2]  A. Oduola,et al.  The Malaria Research and Reference Reagent Resource (MR4) Center--creating African opportunities. , 2001, African journal of medicine and medical sciences.

[3]  Christopher P. Austin,et al.  Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership. , 2012, Cancer research.

[4]  Min-Seok Kwon,et al.  IDMap: facilitating the detection of potential leads with therapeutic targets , 2008, Bioinform..

[5]  Malorye Allison,et al.  NCATS launches drug repurposing program , 2012, Nature Biotechnology.

[6]  C. Vilchèze,et al.  Anthelmintic Avermectins Kill Mycobacterium tuberculosis, Including Multidrug-Resistant Clinical Strains , 2012, Antimicrobial Agents and Chemotherapy.

[7]  Ruili Huang,et al.  The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics , 2011, Science Translational Medicine.

[8]  Developing a framework for understanding and enabling open source drug discovery , 2010, Expert opinion on drug discovery.

[9]  Enrique Seoane-Vazquez,et al.  Incentives for orphan drug research and development in the United States , 2008, Orphanet journal of rare diseases.

[10]  J. Peabody,et al.  The Economics of Orphan Drug Policy in the US , 1995, PharmacoEconomics.

[11]  Jyoti Yadav,et al.  Open Source Drug Discovery , 2008 .

[12]  M. Allarakhia,et al.  Understanding and creating value from open source drug discovery for neglected tropical diseases , 2012, Expert opinion on drug discovery.

[13]  B. Padhy,et al.  Drug repositioning: re-investigating existing drugs for new therapeutic indications. , 2011, Journal of postgraduate medicine.

[14]  Philip E. Bourne,et al.  PROMISCUOUS: a database for network-based drug-repositioning , 2010, Nucleic Acids Res..

[15]  Betty Y. S. Kim,et al.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice , 2002, Nature.

[16]  Luonan Chen,et al.  Network-based drug repositioning. , 2013, Molecular bioSystems.

[17]  湯京平,et al.  Understanding Knowledge as a Commons: From Theory to Practice , 2010 .

[18]  L. Coles,et al.  The Role of Academic Institutions in the Development of Drugs for Rare and Neglected Diseases , 2012, Clinical pharmacology and therapeutics.

[19]  Jun O. Liu,et al.  A clinical drug library screen identifies astemizole as an antimalarial agent , 2006, Nature chemical biology.

[20]  E. Tambuyzer,et al.  Rare diseases, orphan drugs and their regulation: questions and misconceptions , 2010, Nature Reviews Drug Discovery.

[21]  Alexander E. Ivliev,et al.  Drug Target Prediction and Repositioning Using an Integrated Network-Based Approach , 2013, PloS one.

[22]  Kate Marusina,et al.  The CTSA Pharmaceutical Assets Portal - a public-private partnership model for drug repositioning. , 2011, Drug discovery today. Therapeutic strategies.

[23]  Sherry L. Jenkins,et al.  Network analysis of FDA approved drugs and their targets. , 2007, The Mount Sinai journal of medicine, New York.

[24]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[25]  S. Walsh,et al.  Managing knowledge assets under conditions of radical change: The case of the pharmaceutical industry , 2011 .

[26]  Xiaomin Luo,et al.  PDTD: a web-accessible protein database for drug target identification , 2008, BMC Bioinformatics.

[27]  Amanda L. Garner,et al.  Repositioning of an existing drug for the neglected tropical disease Onchocerciasis , 2010, Proceedings of the National Academy of Sciences.

[28]  R. Campbell,et al.  Target repurposing for neglected diseases. , 2011, Future medicinal chemistry.

[29]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[30]  Philip E. Bourne,et al.  Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis , 2009, PLoS Comput. Biol..

[31]  R. Mortara,et al.  Tamoxifen is effective against Leishmania and induces a rapid alkalinization of parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amastigotes. , 2007, The Journal of antimicrobial chemotherapy.

[32]  Cheng Zhu,et al.  Drug repositioning for orphan diseases , 2011, Briefings Bioinform..

[33]  Youwen Zhou,et al.  The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? , 2010, Health policy.

[34]  E. Ostrom,et al.  A Framework for Analyzing the Knowledge Commons : a chapter from Understanding Knowledge as a Commons: from Theory to Practice. , 2005 .

[35]  Laurent Ségalat,et al.  High‐throughput screening and small animal models, where are we? , 2010, British journal of pharmacology.

[36]  A. Renslo,et al.  Drug discovery for neglected tropical diseases at the Sandler Center. , 2011, Future medicinal chemistry.

[37]  Robert B. Russell,et al.  SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..

[38]  B. Lundvall National Systems of Innovation , 1992 .

[39]  Kui Xu,et al.  Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases , 2011, Briefings Bioinform..

[40]  E. Chatelain,et al.  Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? , 2012, International journal for parasitology. Drugs and drug resistance.

[41]  Sean Ekins,et al.  In silico repositioning of approved drugs for rare and neglected diseases. , 2011, Drug discovery today.

[42]  Ramaiah Muthyala,et al.  Orphan/rare drug discovery through drug repositioning , 2011 .

[43]  Tudor I. Oprea,et al.  Drug Repurposing from an Academic Perspective. , 2011, Drug discovery today. Therapeutic strategies.

[44]  K. Green National innovation systems: a comparative analysis , 1996 .

[45]  S. Sundar,et al.  Oral miltefosine for the treatment of Indian visceral leishmaniasis. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[46]  Jaijit Bhattacharya,et al.  Open source drug discovery--a new paradigm of collaborative research in tuberculosis drug development. , 2011, Tuberculosis.